Gavrilyuk Julia I, Wuellner Ulrich, Salahuddin Syed, Goswami Rajib K, Sinha Subhash C, Barbas Carlos F
The Skaggs Institute for Chemical Biology, Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Bioorg Med Chem Lett. 2009 Jul 15;19(14):3716-20. doi: 10.1016/j.bmcl.2009.05.047. Epub 2009 May 18.
Irreversible chemical programming of monoclonal aldolase antibody (mAb) 38C2 has been accomplished with beta-lactam equipped mono- and bifunctional targeting modules, including a cyclic-RGD peptide linked to either the peptide (D-Lys(6))-LHRH or another cyclic RGD unit and a small-molecule integrin inhibitor SCS-873 conjugated to (D-Lys(6))LHRH. We also prepared monofunctional targeting modules containing either cyclic RGD or (D-Lys(6))-LHRH peptides. Binding of the chemically programmed antibodies to integrin receptors alpha(v)beta(3) and alpha(v)beta(5) and to the luteinizing hormone releasing hormone receptor were evaluated. The bifunctional and bivalent c-RGD/LHRH and SCS-783/LHRH, the monofunctional and tetravalent c-RGD/c-RGD, and the monofunctional bivalent c-RGD chemically programmed antibodies bound specifically to the isolated integrin receptor proteins as well as to integrins expressed on human melanoma M-21 cells. c-RGD/LHRH, SCS-783/LHRH, and LHRH chemically programmed antibodies bound specifically to the LHRH receptors expressed on human ovarian cancer cells. This approach provides an efficient, versatile, and economically viable route to high-valency therapeutic antibodies that target defined combinations of specific receptors. Additionally, this approach should be applicable to chemically programmed vaccines.
利用配备β-内酰胺的单功能和双功能靶向模块,包括与肽(D-Lys(6))-LHRH或另一个环RGD单元连接的环RGD肽,以及与(D-Lys(6))LHRH缀合的小分子整合素抑制剂SCS-873,实现了单克隆醛缩酶抗体(mAb)38C2的不可逆化学编程。我们还制备了含有环RGD或(D-Lys(6))-LHRH肽的单功能靶向模块。评估了化学编程抗体与整合素受体α(v)β(3)和α(v)β(5)以及促黄体生成素释放激素受体的结合。双功能和二价的c-RGD/LHRH和SCS-783/LHRH、单功能和四价的c-RGD/c-RGD以及单功能二价的c-RGD化学编程抗体特异性结合分离的整合素受体蛋白以及人黑色素瘤M-21细胞上表达的整合素。c-RGD/LHRH、SCS-783/LHRH和LHRH化学编程抗体特异性结合人卵巢癌细胞上表达的LHRH受体。这种方法为靶向特定受体定义组合的高价治疗性抗体提供了一条高效、通用且经济可行的途径。此外,这种方法应该适用于化学编程疫苗。